NervGen Pharma Corp.
NGEN.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.99M | 7.56M | 8.37M | 7.26M | 6.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.95M | 18.22M | 19.04M | 18.75M | 18.23M |
| Operating Income | -17.95M | -18.22M | -19.04M | -18.75M | -18.23M |
| Income Before Tax | -31.65M | -18.50M | -19.36M | -18.50M | -17.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.65 | -18.50 | -19.36 | -18.50 | -17.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.65M | -18.50M | -19.36M | -18.50M | -17.49M |
| EBIT | -17.95M | -18.22M | -19.04M | -18.75M | -18.23M |
| EBITDA | -17.91M | -18.18M | -19.00M | -18.71M | -18.17M |
| EPS Basic | -0.43 | -0.26 | -0.27 | -0.26 | -0.25 |
| Normalized Basic EPS | -0.27 | -0.16 | -0.17 | -0.16 | -0.16 |
| EPS Diluted | -0.43 | -0.26 | -0.27 | -0.26 | -0.25 |
| Normalized Diluted EPS | -0.27 | -0.16 | -0.17 | -0.16 | -0.16 |
| Average Basic Shares Outstanding | 289.30M | 285.78M | 282.68M | 280.68M | 270.22M |
| Average Diluted Shares Outstanding | 289.30M | 285.78M | 282.68M | 280.68M | 270.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |